(Q46727246)

24 December 2017

title

Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells (English)

1 reference

24 December 2017

1 reference

1 reference

Xu RH

1

1 reference

24 December 2017

Pelicano H

2

1 reference

24 December 2017

Zhang H

3

1 reference

24 December 2017

Giles FJ

4

1 reference

24 December 2017

Keating MJ

5

1 reference

24 December 2017

Huang P

6

1 reference

24 December 2017

publication date

1 December 2005

1 reference

24 December 2017

published in

Leukemia

1 reference

24 December 2017

volume

19

1 reference

24 December 2017

page(s)

2153-2158

1 reference

24 December 2017

issue

12

1 reference

24 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403968

exact match

0 references

cites work

Cancer metabolism: facts, fantasy, and fiction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403968

Recently elucidated energy catabolism pathways provide opportunities for novel treatments in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403968

Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-d-glucose in tumor cells treated under hypoxic vs aerobic conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403968

2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403968

Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403968

Mammalian TOR: a homeostatic ATP sensor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403968

The TOR pathway: a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403968

Upstream and downstream of mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403968

TOR, a central controller of cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403968

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403968

Mammalian target of rapamycin inhibition as therapy for hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403968

Inhibitors of the mammalian target of rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403968

Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403968

Therapeutic potential of target of rapamycin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403968

Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21(Cip1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403968

Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403968

Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycinassociated protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403968

On the Origin of Cancer Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403968

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.LEU.2403968

1 reference

24 December 2017

PubMed ID

16193082

1 reference

24 December 2017